Bio Green Med Solution, Inc. key statistics and ratios
In fiscal 2025, Bio Green Med Solution, Inc. had return on equity of -128.4% and a net margin of -401.3%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net margin | <−999% | <−999% | <−999% | <−999% | −936.6% | <−999% | −737.8% | <−999% | — | <−999% | — | — | — | <−999% | <−999% | −401.3% | −120.5% |
| Return on equity | — | −104.0% | −68.6% | −89.3% | −53.4% | −78.0% | −70.8% | −71.2% | −41.5% | −39.4% | −34.8% | −52.0% | −79.0% | — | — | −128.4% | −31.4% |
| Return on assets | — | −50.9% | −53.1% | −58.1% | −37.0% | −59.7% | −53.0% | −53.1% | −32.7% | −31.8% | −29.8% | −46.2% | −59.6% | −122.4% | −173.8% | −48.8% | −27.4% |
| R&D as % of revenue | >999% | >999% | >999% | >999% | >999% | >999% | 636.9% | >999% | — | >999% | — | — | — | >999% | >999% | 113.5% | — |
| SG&A as % of revenue | 937.2% | >999% | 935.9% | >999% | 717.8% | 339.9% | 294.9% | 654.3% | — | >999% | — | — | — | >999% | >999% | — | — |
| Quarter | 2024 Q1Mar 2024 | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Net margin | <−999% | <−999% | <−999% | — | <−999% | −91.7% | −26.5% | −120.5% |
| R&D as % of revenue | >999% | >999% | >999% | — | 6.2% | −7.1% | — | — |
| SG&A as % of revenue | >999% | >999% | >999% | — | — | — | — | — |
Financial health
- Short-term assets cover short-term liabilities $6m of assets due within a year against $692,000 of liabilities due within a year.
- Short-term assets cover long-term liabilities $6m short-term assets against $2,000 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Weak moat
How hard Bio Green Med Solution's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -45.6% of total assets over 10 years.
- Durability 10 / 20
Operating margin has been a median -3548.0%; its worst year was -16794.3%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 7 years, at a median -1698.1% of revenue.
- Discipline 0 / 20
The diluted share count rose 11199.7% over five years; stock-based pay has been a median 123.0% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
Compare with peers
- Cheetah NET Supply Chain Service Inc. statistics
- Inneova Holdings Ltd statistics
- One & One Green Technologies. Inc statistics
- Alliance Entertainment Holding Corp statistics
- Gigacloud Technology Inc statistics
Head to head: BGMS vs CTNTBGMS vs INEOBGMS vs YDDL
More: Distributors stocks compared, Consumer Discretionary sector, rankings of US companies